CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.56B, above the global median of $1.15B
- PositionGross margin is -98.2%, lower than 95% of its Biotechnology peers (median 78%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
1.56BUSDvs all stocks (USD)
Revenue (TTM)
66.41MUSDvs all stocks (USD)
Beta
0.9950xvs all stocks
52-Week Change
-53.98%vs all stocks
Market Capitalization
1.56BUSDvs all stocks (USD)
Enterprise Value
978.47MUSDvs all stocks (USD)
Forward P/E
-3.13xvs Biotechnology peers
Price to Sales (TTM)
23.54xvs Biotechnology peers
Price to Book (MRQ)
1.53xvs Biotechnology peers
Enterprise to Revenue
14.73xvs Biotechnology peers
Enterprise to EBITDA
-1.95xvs Biotechnology peers
Gross Margin
-98.22%vs Biotechnology peers
Operating Margin
-1985.55%vs Biotechnology peers
Return on Assets (TTM)
-27.66%vs Biotechnology peers
Return on Equity (TTM)
-57.16%vs Biotechnology peers
Revenue (TTM)
66.41MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.1390USDUpdated Jul 19, 2026Quarterly Revenue Growth
-56.10%vs Biotechnology peers
Gross Profit (TTM)
-428.74MUSDvs all stocks (USD)
EBITDA (TTM)
-501.23MUSDvs all stocks (USD)
Net Income (TTM)
-559.78MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-57.48%vs Biotechnology peers
Operating Cash Flow (TTM)
-320.95MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-177.80MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
74.26MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
70.95MUSDFY2025 · Dec 31, 2025Gross Profit
3.30MUSDFY2025 · Dec 31, 2025Operating Income
-648.13MUSDvs all stocks (USD)
Pre-tax Income
-644.89MUSDFY2025 · Dec 31, 2025Income Tax Expense
-136.00KUSDFY2025 · Dec 31, 2025Net Income
-644.76MUSDFY2025 · Dec 31, 2025EBIT
-643.09MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-559.38MUSDFY2025 · Dec 31, 2025Research & Development
475.27MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
176.59MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-425.00KUSDFY2025 · Dec 31, 2025Non-operating Interest Income
22.79MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
1.81MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.44USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.44USDFY2025 · Dec 31, 2025Basic Shares Outstanding
447.45MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
447.45MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-644.76MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-422.39MUSDFY2025 · Dec 31, 2025Free Cash Flow
-428.86MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
753.92MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-644.76MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
83.70MUSDFY2025 · Dec 31, 2025Stock-based Compensation
111.22MUSDFY2025 · Dec 31, 2025Other Non-cash Items
53.88MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
32.94MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-2.62MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-56.76MUSDFY2025 · Dec 31, 2025Capital Expenditures
-6.47MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-2.16MUSDFY2025 · Dec 31, 2025Net Acquisitions
-4.44MUSDFY2025 · Dec 31, 2025Purchase of Investments
-3.81MUSDFY2025 · Dec 31, 2025Sale of Investments
0.00USDFY2025 · Dec 31, 2025Net Investing Cash Flow
-14.71MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-8.43MUSDFY2025 · Dec 31, 2025Other Financing Charges
-3.00MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
517.44MUSDFY2025 · Dec 31, 2025Shares Outstanding
530.63MSharesUpdated Jul 19, 2026Float Shares
513.01MSharesUpdated Jul 19, 2026Shares Short
172.30MSharesUpdated Jul 19, 2026Short Ratio
7.99daysvs all stocks
Short % of Shares Outstanding
34.41%vs all stocks
% Held by Insiders
2.37%vs all stocks
% Held by Institutions
68.86%vs all stocks
Total Cash (MRQ)
654.47MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.24USDUpdated Jul 19, 2026Total Debt (MRQ)
72.38MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0706xvs Biotechnology peers
Current Ratio (MRQ)
5.47xvs Biotechnology peers
Book Value per Share (MRQ)
1.93USDUpdated Jul 19, 2026Total Assets
1.47BUSDvs all stocks (USD)
Total Current Assets
812.85MUSDFY2025 · Dec 31, 2025Total Liabilities
343.26MUSDFY2025 · Dec 31, 2025Total Non-current Assets
661.28MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
195.56MUSDFY2025 · Dec 31, 2025Total Current Liabilities
147.71MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
743.29MUSDFY2025 · Dec 31, 2025Accounts Payable
18.12MUSDFY2025 · Dec 31, 2025Short-term Debt
21.75MUSDFY2025 · Dec 31, 2025Deferred Revenue
37.60MUSDFY2025 · Dec 31, 2025Long-term Debt
56.21MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
2.08MUSDFY2025 · Dec 31, 2025Common Stock (Book)
5.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-2.08BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.13BUSDvs all stocks (USD)
52-Week Low
2.77USDUpdated Jul 19, 202652-Week High
7.18USDUpdated Jul 19, 202652-Week Change
-53.98%vs all stocks
Beta
0.9950xvs all stocks
50-Day MA
3.32USDUpdated Jul 19, 2026200-Day MA
4.03USDUpdated Jul 19, 2026Avg 10-Day Volume
26.18MSharesUpdated Jul 19, 2026Avg 30-Day Volume
23.76MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.16USDUpdated Jul 19, 2026Other Income / Expense
-17.74MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is -98.2%, lower than 95% of its Biotechnology peers (median 78%)Significant
Gross margin: -0.98Industry median: 0.78Industry P5: 0.18Peers compared: 197
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 23.54Revenue Growth YoY: -0.56
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 5.47Altman Z-Score: -0.09
Financial Health
Altman Z-Score -0.09: distress zoneCritical
Altman Z-Score: -0.09
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.56B, above the global median of $1.15BNotable
Market cap (USD): 1,563,094,673Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Hualan Biological Engineering Inc.
Tier 1ProductionApproval-Gated PipelineRule
Enovis Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Green Thumb Industries Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Maze Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Forte Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Harbin Gloria Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sihuan Pharmaceutical Holdings Group Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Arrivent Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Classys Inc.
Tier 1ProductionApproval-Gated PipelineRule
Yantai Dongcheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
A2Z Cust2Mate Solutions Corp
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Beam Therapeutics Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Wave Life Sciences Ltd.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC